Alnylam Pharmaceuticals (ALNY) Non Operating Investment Income (2014 - 2017)
Alnylam Pharmaceuticals (ALNY) posted Non Operating Investment Income of -$345000.0 for Q2 2017, up 77.73% on a QoQ basis from -$1.5 million in Q1 2017, and down 136.16% year-over-year from $954000.0 in Q2 2016.
Alnylam Pharmaceuticals (ALNY) Non Operating Investment Income (2014 - 2017) Analysis & Trends
Alnylam Pharmaceuticals' Non Operating Investment Income history runs 3 years deep, the most recent figure standing at -$345000.0 for Q2 2017.
- Quarterly Non Operating Investment Income fell 136.16% year-over-year to -$345000.0 in Q2 2017, while the trailing twelve-month figure through Dec 2017 was -$1.9 million (down 127.15% YoY) and the FY2017 annual result came in at -$1.9 million, down 127.15% from the prior year.
- Non Operating Investment Income was -$345000.0 for Q2 2017 at Alnylam Pharmaceuticals, up from -$1.5 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $5.2 million in Q1 2016 and bottomed at -$1.5 million in Q1 2017.
- A 3-year average of $895500.0 and a median of $636500.0 in 2014 frame the typical range for Non Operating Investment Income.
- Peak annual rise in Non Operating Investment Income reached 130.04% in 2017, while the deepest fall reached 136.16% in 2017.
- Alnylam Pharmaceuticals' Non Operating Investment Income stood at $1.5 million in 2014, then sank by 89.37% to $161000.0 in 2016, then tumbled by 314.29% to -$345000.0 in 2017.
- Business Quant data shows ALNY's Non Operating Investment Income at -$345000.0 in Q2 2017, -$1.5 million in Q1 2017, and $161000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -345,000.00 |
| Jun 30, 2017 | -345,000.00 |
| Mar 31, 2017 | -1.55 Mn |
| Mar 31, 2017 | -1.55 Mn |
| Dec 31, 2016 | 161,000.00 |
| Dec 31, 2016 | 161,000.00 |
| Sep 30, 2016 | 706,000.00 |
| Sep 30, 2016 | 706,000.00 |
| Jun 30, 2016 | 954,000.00 |
| Jun 30, 2016 | 954,000.00 |
| Mar 31, 2016 | 5.16 Mn |
| Mar 31, 2016 | 5.16 Mn |
| Dec 31, 2014 | 1.51 Mn |
| Dec 31, 2014 | 1.51 Mn |
| Sep 30, 2014 | 567,000.00 |
| Sep 30, 2014 | 567,000.00 |